Authors
Latest:
Planning Ahead for a CareerThe 3 years of my fellowship training were a life-changing experience that will stay with me forever.
Latest:
Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized SarcomaAs clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.
Latest:
Providing Oncology Services in Impoverished CountriesMany of us training in the United States have encountered patients and their families from resource-limited regions of the world-families who have uprooted themselves for the chance to save the lives of their children diagnosed with cancer.
Latest:
Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian CancerDiana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.
Latest:
Top 3 Must Do's to Prepare for Managed Care in 2016Although there still are many unknowns, especially in light of this being an election year that will bring a new administration, it’s already very clear how the transition to value is affecting oncology practices.
Latest:
Moving to Electronic Prior Authorization Requires Incremental StepsIn a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1
Latest:
Dr. Bodurka on the Increasing Number of Cancer SurvivorsDr. Diane Bodurka, from the MD Anderson Cancer Center, on the Increasing Number of Cancer Surivors
Latest:
Merging Community Practices With an Academic Cancer CenterConsolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Latest:
Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETsDiane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.
Latest:
Dr Simeone on the EVEREST-1 Trial Evaluating A2B530 in Solid TumorsDiane M. Simeone, MD, discusses the phase 1/2 EVEREST-1 trial evaluating the autologous CAR T-cell therapy A2B530 in patients with solid tumors.
Latest:
Dr Reidy-Lagunes on the Evolving NET Treatment ParadigmDiane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.
Latest:
Future Directions in the Management of Neuroendocrine TumorsLooking toward the future management of neuroendocrine tumors, Diane Reidy-Lagunes, MD, shares insight on possible therapy evolutions and ongoing unmet needs.
Latest:
Dr. Simone Discusses the Precision Promise Trial in Pancreatic CancerDiane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.
Latest:
Politics & Policy: March 2007The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.
Latest:
Marking 25 Years of Progress in Blood and Marrow TransplantationWhile major accomplishments in blood and marrow transplantation (BMT) were being made around the country, the first BMT program at Wake Forest Baptist came into view, a vision brought to life by David D. Hurd, MD.
Latest:
Dr. Ko on Renal Transplantation Following Tumor ExcisionDicken Shiu-Chung Ko, MD, Department of Urology, Massachusetts General Hospital, discusses current evidence of renal transplantation following tumor excision.
Latest:
Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCLDiego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.
Latest:
Clinical Development of Regorafenib Combinations in Pediatric RhabdomyosarcomaDieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the clinical development of regorafenib (Stivarga) combinations in pediatric rhabdomyosarcoma.
Latest:
Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in LymphomaDimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Dimosthenis on Prognosis Factors in Ewing SarcomaDimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognosis factors in patients with Ewing sarcoma.
Latest:
Landmark Trial Puts Robotic Surgery to the Test in Bladder CancerVivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.
Latest:
Dr. Dirk Arnold Discusses the CONSIGN StudyDirk Arnold, MD, Director Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, Arnold Discusses the CONSIGN Study.
